# A Dose-finding Trial of ETC-1002(Bempedoic Acid) in Patients With Hypercholesterolemia

> **NCT04784442** · PHASE2 · COMPLETED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 188 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** 180mg of ETC-1002(bempedoic acid)
- **DRUG:** 120mg of ETC-1002(bempedoic acid)
- **DRUG:** 60mg of ETC-1002(bempedoic acid)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04784442
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-24
- **Primary completion:** 2022-04-18
- **Final completion:** 2022-05-17
- **Target enrollment:** 188 (ACTUAL)
- **Last updated:** 2024-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04784442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04784442, "A Dose-finding Trial of ETC-1002(Bempedoic Acid) in Patients With Hypercholesterolemia". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04784442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*